Acadia Pharmaceuticals Inc. (ACAD) fair value analysis
Nasdaq · Updated 2026-10-19
ACAD price how computed
Forward Fair Value verdict
OvervaluedACAD is trading at a 10–25% premium to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $19.12
- Sector
- Healthcare
- 12-month range
- $18.62–$30.57
- Market cap
- $3.29B
- From 52-week high
- -37.5%
- Shares outstanding
- 172M
- Rank in Healthcare by discount to fair value
- #74 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company that develops and commercializes medicines for central nervous system disorders, including schizophrenia, depression, and other psychiatric and neurological conditions. The company operates in the United States and international markets, conducting research, development, and sales activities across multiple regions.
ACAD currently ranks #74 of 108 Healthcare stocks by discount to fair value. It has screened as Overvalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $3.29B
- P/E (trailing)
- 32x
- Revenue (TTM)
- $1.14B
- Net margin
- 33.4%
- EPS (TTM)
- $0.60
- Gross margin
- 90.8%
- Debt / equity
- 0.06
- Revenue growth (3-yr avg)
- 15.2%
- Shares outstanding
- 172M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Stable
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 16 · oversold
- 50-day average
- $25.55
- 200-day average
- $24.01
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-04
- Last 8 quarters vs consensus
- 5 beat, 2 missed
- Quarter by quarter
- 2026-06 ▲ beat (+200.0%)
2026-03 ▼ miss (-75.0%)
2025-12 ▼ miss (-1.0%)
2025-09 ▲ beat (+85.7%)
2025-06 ▲ beat (+14.3%)
2025-03 ▬ met (0.0%)
2024-12 ▲ beat (+292.7%)
2024-09 ▲ beat (+42.9%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 15 buy · 4 hold · 1 sell (20 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $30.5
- Target vs last price
- +59.5%
What our data shows for ACAD
- Our model validated 9 trailing price-to-earnings windows for ACAD, built from quarterly earnings records.
- Shares are trading in the lower third of their 12-month price range of $18.62–$30.57.
- The 14-day relative strength index sits at an oversold 16.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for ACAD
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent ACAD news
TickrTrends' derived news-sentiment signal for ACAD is currently leaning positive, computed from recent coverage.
- ACAD Reiterated by Needham -- Price Target Maintained at $35 (gurufocus.com, 2026-10-19)
TickrTrends take: Needham's maintained price target of 35 dollars for ACAD suggests analyst confidence in the company's fundamentals, yet TickrTrends currently derives an Overvalued assessment for the Healthcare sector company. The persistence of this price target amid an Overvalued designation indicates a potential disconnect between traditional analyst valuations and current market pricing that investors focused on valuation metrics may want to monitor. A valuation-conscious reader should track whether market conditions or company fundamentals shift to narrow the gap between the analyst target and the current valuation assessment. - ACAD Downgraded by UBS -- Price Target Lowered to $23.00 (gurufocus.com, 2026-10-13)
TickrTrends take: UBS's downgrade and price target reduction to $23 represents a notable shift in analyst sentiment for ACAD, which aligns with TickrTrends' current assessment that the stock is overvalued. For valuation-conscious investors monitoring the Healthcare sector, this analyst action reinforces the need to track whether the market reprices ACAD toward lower levels or if other fundamental factors might support current valuations. The convergence of the UBS downgrade with the overvalued designation suggests increased scrutiny around ACAD's near-term earnings power and growth prospects relative to its current market price. - Acadia Pharmaceuticals (ACAD) Resolves Nuplazid Patent Dispute, Boosting Market Outlook (gurufocus.com, 2026-10-05)
TickrTrends take: Acadia Pharmaceuticals resolved a patent dispute surrounding Nuplazid, its key revenue-generating treatment, which removes a significant legal overhang that could have impaired future cash flows. TickrTrends currently rates ACAD as overvalued within the Healthcare sector, suggesting the market may already be pricing in optimistic outcomes from this resolution. Investors focused on valuation metrics should monitor whether the company's financial guidance and earnings revisions reflect meaningful improvements sufficient to justify the current stock price, or whether the dispute resolution has already been substantially factored into recent trading.
More ACAD news
- Acadia Pharmaceuticals (ACAD) and Zydus Move to Dismiss Patent Lawsuits Ahead of Nuplazid Trial (gurufocus.com, 2026-10-05)
What people are saying
Follow the ACAD conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — ACAD's sector discount rank improved this week, moving from number 93 to number 88 among Healthcare sector stocks. Despite this improvement in relative valuation positioning, the stock maintains an overvalued assessment according to TickrTrends' derived indicators.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — ACAD's derived indicators shifted this week as the 50/200-day trend state moved from uptrend to mixed, while the RSI zone declined from neutral to oversold territory. The stock's sector discount rank improved to #98 from #111, indicating a relatively stronger valuation position within the Healthcare sector. The current valuation verdict remains Overvalued.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is ACAD stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), ACAD is trading at a 10–25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.
What is ACAD's TickrTrends verdict?
ACAD's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.
How does ACAD compare to other Healthcare stocks?
ACAD ranks #74 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is ACAD overbought or oversold?
ACAD's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does ACAD report earnings next?
ACAD's next earnings report is scheduled for 2026-11-04, per the published earnings calendar.
Does ACAD usually beat earnings estimates?
Over its last 8 reported quarters ACAD beat the consensus estimate 5 times and missed 2 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about ACAD?
Of 20 analysts covering ACAD, 15 rate it a buy, 4 a hold and 1 a sell - buy-leaning, with a consensus price target of $30.5 (+59.5% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
ACAD vs ABBV · ACAD vs BIIB · ACAD vs BMY · ACAD vs CAH · ACAD vs CNC